Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Genes encoding critical transcriptional activators for murine neural tube development and human spina bifida: a case-control study

  • Wei Lu1,
  • Adrian R Guzman1,
  • Wei Yang2,
  • Claudia J Chapa5,
  • Gary M Shaw2,
  • Robert M Greene3,
  • M Michele Pisano3,
  • Edward J Lammer4,
  • Richard H Finnell5 and
  • Huiping Zhu5Email author
BMC Medical Genetics201011:141

DOI: 10.1186/1471-2350-11-141

Received: 1 June 2010

Accepted: 8 October 2010

Published: 8 October 2010

Abstract

Background

Spina bifida is a malformation of the neural tube and is the most common of neural tube defects (NTDs). The etiology of spina bifida is largely unknown, although it is thought to be multi-factorial, involving multiple interacting genes and environmental factors. Mutations in transcriptional co-activator genes-Cited2, p300, Cbp, Tfap2α, Carm1 and Cart1 result in NTDs in murine models, thus prompt us to investigate whether homologues of these genes are associated with NTDs in humans.

Methods

Data and biological samples from 297 spina bifida cases and 300 controls were derived from a population-based case-control study conducted in California. 37 SNPs within CITED2, EP300, CREBBP, TFAP2A, CARM1 and ALX1 were genotyped using an ABI SNPlex assay. Odds ratios and 95% confidence intervals were calculated for alleles, genotypes and haplotypes to evaluate the risk for spina bifida.

Results

Several SNPs showed increased or decreased risk, including CITED2 rs1131431 (OR = 5.32, 1.04~27.30), EP300 rs4820428 (OR = 1.30, 1.01~1.67), EP300 rs4820429 (OR = 0.50, 0.26~0.50, in whites, OR = 0.7, 0.49~0.99 in all subjects), EP300 rs17002284 (OR = 0.43, 0.22~0.84), TFAP2A rs3798691 (OR = 1.78, 1.13~2.87 in Hispanics), CREBBP rs129986 (OR = 0.27, 0.11~0.69), CARM1 rs17616105 (OR = 0.41, 0.22~0.72 in whites). In addition, one haplotype block in EP300 and one in TFAP2A appeared to be associated with increased risk.

Conclusions

Modest associations were observed in CITED2, EP300, CREBBP, TFAP2A and CARM1 but not ALX1. However, these modest associations were not statistically significant after correction for multiple comparisons. Searching for potential functional variants and rare causal mutations is warranted in these genes.

Background

Studies using genetically modified mouse models have contributed a great deal to our understanding of molecular mechanisms that govern critical embryonic development processes, such as neural tube closure. Among the over 200 existing mouse models for neural tube defects (NTDs), several harbor mutations in genes encoding transcriptional activators or co-activators, such as Cited2, Crebbp, p300, Tfap2α, Carm1 and Cart1 [19].

CREB binding protein (CREBBP; CBP) was originally identified as a protein that binds to the phosphorylated form of the CREB transcription factor and increases the expression of genes containing CRE elements. It is closely related to the adenovirus E1A-associated protein p300. CBP and p300 are functionally redundant histone deacetylases essential for proliferation and embryonic development [5, 8, 10]. Both Crebbp and p300 genes are expressed at high level in the neural folds at embryonic day E8.5 in mice [3]. Homozygous deletions of either the Crebbp or p300 genes in mice results in lethality on E9~11, with subsequent defects in neurulation, cell proliferation and cardiac development [5, 8].

The methylation of the Crebbp/p300 complex is catalyzed by co-activator-associated arginine methyltransferase (CARM1). This process disables the recruitment of cAMP response element binding protein (CREB). Thus, CARM1 functions as a co-repressor in the cAMP signaling pathway, via its methyltransferase activity [11]. In addition to its enzymatic function, CARM1 is also required for NF-kappaB-dependent gene expression as a transcriptional cofactor [12]. Carm1 gene expression was observed in the fore- and hindbrain, neural folds, somites and posterior lateral plates of E8.25 mouse embryos, and later on in development (E8.75) expression became prominent in the neural tube and somites [13].

CITED2 is a nuclear co-activator that binds to CBP/p300. Disruption of the Cited2 gene in mice is embryonic lethal, with the mice dying secondary to significant defects in the development of the neural tube and the heart [2, 6, 14, 15]. The interaction of CBP and p300 with Cited2 is required for activation of important transcriptional factors such as AP-2α [1, 16]. Mice carrying homozygous disruptions of the gene coding for the protein AP-2 α (Tfap2 α) die at term as a result of severe developmental abnormalities. The earliest defect observed was a complete failure of neural tube closure in the cranial region, and it has been suggested in a chimera model study that there is an independent requirement for AP-2 α in the formation of the neural tube [1719].

CART1 is a paired-class homeobox-containing transcription factor regulated by CBP/p300 acetylation of a highly conserved lysine residue that increases the interaction between CBP/p300 and CART1, ultimately enhancing its transcriptional activation [20]. The Cart1 gene is expressed in chondrocytes [21, 22], and appears to be required for embryonic forebrain mesenchymal survival. The absence of CART1 disrupts cranial neural tube morphogenesis by blocking the initiation of closure in the midbrain region. Homozygous Cart1 mutant mice are born alive with neural tube closure defects including acrania and meroanencephaly, but die soon after birth [9]. The Cart1 knockout mouse is among several NTD mouse models that can be rescued by maternal supplementation with folic acid [23]. The gene encoding human CART1 is ALX1 (ALX homobox 1). In summary, CBP, p300, CARM1, TFAP2α, CITED2 and CART1 are transcriptional activator/co-activators that contributes to the ontogeny of the neural tube in mammalian systems. Whether gene homologues are associated with human NTDs remains unknown. Three single nucleotide polymorphisms (SNP) in the un-translated region of CITED2 gene were studied in a group of patients with spina bifida and controls, modest associations were observed but results were imprecise owing to small sample size [14]. Mutations in the human CBP gene have been identified as being responsible for the Rubinstein-Taybi syndrome (RTS), which has a defined craniofacial phenotype [4]. The purpose of this study is to evaluate the potential association between variations among human CITED2, CREBBP, EP300, TFAP2A, CARM1 and ALX1 genes and the risk for spina bifida.

Methods

Study Population

Data and biological samples were obtained from a case-control study conducted by the California Birth Defects Monitoring Program (CBDMP). The CBDMP is an active, population-based surveillance system for collecting information on infants and fetuses with structural congenital malformations, which has been described elsewhere [24]. Included were 297 singleton infants with spina bifida (cases) and 300 non-malformed infants (controls). Both cases and controls were randomly selected from the samples with bloodspots available. Cases were selected from California Birth Defect Registry 1990-1999; non-malformed controls were selected from Vital Statistics matching the birth years with the selected cases. Case and control infants were linked to their newborn screening bloodspots. All samples were obtained with approval from the State of California Health and Welfare Agency Committee for the Protection of Human Subjects.

Candidate genes and SNPs

The 6 candidate genes and SNPs genotyped are listed in Table 1. Tagging SNPs were selected for each candidate gene using the SNPbrowser™ Software (ABI, Foster City, CA) based on data from the four HapMap populations (CEU, YRI, JPT and CHB) [25]. All validated tagging SNPs with pairwise r2 > = 0.8 with a minor allele frequency (MAF) no less than 5% were included for genotyping. Also included for study were all non-synonymous coding SNPs in these genes. Based on these criteria, 37 SNPs were genotyped.
Table 1

Characteristics of all genotyped SNPs

Gene

(Alias)

Marker

Chromosome

Chromosome position

RefSNP alleles

Call Rate

(%)

MAF*

(All subjects)

HWE P

(controls)

MAF

(White)

HWE** P

(White controls)

MAF

(Hispanic)

HWE P

(Hispanic controls)

ALX1 (CART1)

rs11608773

12

84229006

A/G

100.0

0.229

0.435

0.274

0.478

0.217

0.391

 

rs4761130

12

84226396

C/T

99.8

0.421

0.286

0.358

0.154

0.401

0.465

 

rs7295242

12

84222948

A/G

100.0

0.161

0.781

0.074

0.557

0.159

0.358

CARM1

rs11667234

19

10880581

A/C

99.8

0.021

0.010

0.039

0.071

0.016

0.934

 

rs11670365

19

10865833

C/T

100.0

0.056

0.918

0.084

0.754

0.045

0.702

 

rs1529711

19

10884434

A/G

99.7

0.097

0.492

0.161

0.932

0.081

0.519

 

rs1541596

19

10848013

A/G

99.5

0.475

0.326

0.497

0.969

0.408

0.957

 

rs17616105

19

10883159

C/T

100.0

0.189

0.732

0.235

0.365

0.152

0.072

 

rs7254708

19

10863579

A/G

100.0

0.071

0.043

0.123

0.116

0.059

0.441

CITED2

rs1131431

6

139735527

A/G

100.0

0.153

0.273

0.200

0.624

0.121

0.948

 

rs7775752

6

139737486

A/G

45.1

0.007

0.957

0.009

0.913

0.006

1.000

CREBBP (CBP)

rs11076783

16

3722706

C/T

100.0

0.154

0.638

0.116

0.142

0.139

0.802

 

rs11076785

16

3730187

G/T

46.6

0.457

0.638

0.401

0.185

0.457

0.463

 

rs11076786

16

3751597

C/T

100.0

0.075

0.008

0.077

0.441

0.046

0.637

 

rs129986

16

3744242

C/T

100.0

0.023

0.530

0.032

0.590

0.020

0.735

 

rs130003

16

3768173

A/G

99.8

0.015

0.792

0.032

0.711

0.010

0.967

 

rs130008

16

3721953

C/G

99.8

0.011

0.838

0.032

0.752

0.001

1.000

 

rs17136507

16

3740546

C/T

100.0

0.178

0.536

0.110

0.229

0.227

0.449

 

rs886528

16

3751557

C/T

99.7

0.383

0.590

0.390

0.986

0.368

0.839

 

rs9392

16

3715170

A/G

99.8

0.189

0.566

0.223

0.625

0.138

0.700

EP300 (P300)

rs17002284

22

39826792

A/G

100.0

0.265

0.220

0.313

0.745

0.217

0.522

 

rs17433014

22

39829768

A/G

99.8

0.018

0.769

0.029

0.793

0.019

0.834

 

rs2230111

22

39851949

A/G

99.8

0.002

0.977

0.006

0.959

1.000

1.000

 

rs4820428

22

39867535

A/G

100.0

0.446

0.006

0.329

0.822

0.419

0.667

 

rs4820429

22

39868057

C/G

100.0

0.159

0.382

0.258

0.040

0.124

0.471

 

rs4822006

22

39849308

C/T

100.0

0.247

0.844

0.355

0.587

0.185

0.740

 

rs5758246

22

39871792

A/G

100.0

0.030

0.635

1.000

1.000

0.012

0.934

 

rs9611502

22

39861182

C/T

100.0

0.014

0.838

0.019

0.918

0.013

0.867

TFAP2A (AP2)

rs10456013

6

10506548

G/T

100.0

0.032

0.592

0.048

0.670

0.026

0.735

 

rs1621700

6

10528084

A/G

99.7

0.288

0.671

0.252

0.081

0.357

0.773

 

rs303050

6

10511169

C/T

100.0

0.257

0.061

0.165

0.259

0.262

0.267

 

rs303055

6

10527462

C/T

100.0

0.353

0.150

0.435

0.569

0.335

0.025

 

rs303056

6

10528467

C/G

100.0

0.159

0.229

0.094

0.477

0.126

1.000

 

rs3798691

6

10519381

C/G

100.0

0.112

0.021

0.042

0.011

0.134

0.111

 

rs3798694

6

10516743

A/G

100.0

0.062

0.122

0.087

0.225

0.059

0.293

 

rs533558

6

10503558

A/G

100.0

0.441

0.848

0.361

0.955

0.481

0.858

 

rs537112

6

10503192

A/G

100.0

0.180

0.571

0.103

0.754

0.195

0.255

*MAF: minor allele frequency; **HWE: Hardy-Weinberg Disequilibrium

Genotyping Approach

DNA was extracted from blood spots using the Gentra Puregene DNA Extraction Kit (Qiagen, Valencia, CA) following the standard protocol. Prior to genotyping, genomic DNA was amplified using a commercially available multiple displacement amplification (MDA) kit, GenomiPhi DNA Amplification kit (GE Healthcare, Piscataway, NJ). The whole genome amplification (WGA) product was then quantified using RNase P assay (AppliedBiosystems, Foster City, CA). 200 ng of WGA product was used for the SNPlex assay containing the 37 SNPs. All genotyping assays were performed blinded to subjects' case or control status.

The SNPs selected for analyses were submitted to Applied Biosystems to create a unique SNPlex assay. The SNPlex™ genotyping system (Applied Biosystems, Foster City, CA) is based on a universal multiplexed oligonucleotide ligation assay (OLA)/PCR and drag chute mobility modifier technology. The resulting genotype data were analyzed using GeneMapper™ v4.0 (Applied Biosystems, Foster City, CA).

Analytic procedures

Analyses were performed for the overall study group as well as for specific ethnic/race groups. Hispanic infants were further subdivided into those whose mothers were born in the United States, or native-born (Hisp-NB) and those whose mothers were not, or foreign-born (Hisp-FB), as it has been shown that these two groups are different with respect to ethnic composition and social economic status [26, 27]. Departure from Hardy-Weinberg Equilibrium (HWE) was assessed by Chi-square analysis in each subgroup using data from controls only. Odds ratios (OR) for SNP genotypes were calculated using logistic regression analyses. Since the mode of inheritance is unknown, potential associations with spina bifida risk were evaluated assuming dominant, recessive and additive models for each SNP. Chi-square tests were used to assess the significance of dominant and recessive models. Cochran-Armitage trend tests were used to assess the significance of additive models. If numbers were less than 5, Fisher's exact test and Exact Armitage trend test were applied. Analyses were performed using SVS v7.1.1 (GoldenHelix, Bozeman, MT) software. The false discovery rate (FDR) [28] was used to account for multiple testing (data not shown). Haplotype blocks were constructed using HaploView 4.2 http://www.broadinstitute.org/haploview/haploview in each race/ethnicity group with pair-wise D'≥0.85. Haplotype frequencies were estimated based on the Maximum Expectation (EM) algorithm. Association of each haplotype was evaluated by calculating ORs and 95% confidence intervals against all other haplotypes. Estimated risks were considered statistically precise if 95% confidential interval of OR does not include 1.00.

Results and Discussion

Demographic characteristics of the cases and controls are listed in Table 2. Cases and controls were similar with respect to maternal age, parity, and plurality but expectedly differed with respect to race/ethnicity and maternal educational attainment. That is, the data revealed greater frequencies of Hispanics (primarily foreign born) and women with low educational level (less than high school) in the spina bifida case group.
Table 2

Demographic distribution of malformed cases and non-malformed controls, California 1990-1999

Variable

Spina Bifida

 

Cases

n = 297 (%1)

Controls

n = 300 (%1)

Maternal Race/Ethnicity

  

   White, non-Hispanic

59 (19.9)

96 (32.0)

   Hispanic, Native Born

33 (11.1)

33 (11.0)

   Hispanic, Foreign Born

166 (55.9)

115 (38.3)

   Black

17 (5.7)

20 (6.7)

   Asian

9 (3.0)

25 (8.3)

   Other

9 (3.0)

11 (3.7)

Maternal age at delivery (years)

  

   13-24

128 (43.1)

123 (41.0)

   25-29

80 (26.9)

71 (23.7)

   30-34

47 (15.8)

64 (21.3)

   35-55

39 (13.1)

42 (14.0)

Maternal education

  

   Less than high school

158 (53.2)

110 (36.7)

   High School

65 (21.9)

81 (27.0)

   Greater than High school

71 (23.9)

109 (36.3)

Parity

  

   0

120 (40.4)

114 (38.0)

   1

88 (29.6)

101 (33.7)

   ≥ 2

86 (29.0)

84 (28.0)

Plurality

  

   Singleton

287 (96.6)

293 (97.7)

   Multiple births

8 (2.7)

7 (2.3)

Infant Sex

  

   Male

146 (49.2)

149 (49.7)

   Female

151 (50.8)

151 (50.3)

1Percentages may not equal 100 owing to missing data or rounding.

Genotyping of 37 SNPs was performed using a custom-made Applied Biosystems SNPlex panel. Due to low call rates, two SNPs, rs7775752 (45.1%) and rs11076785 (46.6%), were excluded from analysis. Departure from HWE in the controls (p < 0.01) was observed in rs11076786 and rs4820428 when analyzing the whole dataset. This deviation was eliminated when stratified by race/ethnicity (Table 1). Several SNPs and haplotypes containing these SNPs showed modest associations with spina bifida risk (p ≤ 0.05, Table 3 and 4). These associations are summarized below for each gene. The results, however, are largely indicative of no or very limited associations, particularly after correction for multiple comparisons.
Table 3

Allele associations (P < 0.05) among subgroups

SNP

Gene

Ethnicity

refSNP alleles

Minor Allele

Ratio Counts

(Case, Control)

P value

Odds Ratio

95% CI

rs129986

CREBBP (CBP)

white

C/T

T

118:0, 182:10

0.008*

n/a

n/a

rs17616105

CARM1

white

C/T

C

101:17, 136:56

0.003

2.45

1.34-4.46

rs303056

TFAP2A (AP2)

white

C/G

C

16:102, 13:179

0.046

2.16

1.00-2.15

rs3798691

TFAP2A (AP2)

Hispanic

C/G

C

65:333, 29:267

0.013

1.80

1.13-2.87

  

Hispanic-FB

C/G

C

52:280, 22:208

0.036

1.76

1.03-2.98

rs533558

TFAP2A (AP2)

Hispanic-NB

A/G

G

36:30, 24:42

0.036

2.10

1.05-4.22

rs4820428

EP300 (P300)

All subjects

A/G

G

276:240, 229:259

0.038

1.30

1.01-1.67

Table 4

Genotype associations (P < 0.05) among subgroups under different modes of inheritance

Marker

Gene

Ethnicity

P value

Mode of Inheritance

Odds Ratio

[(ratio count (case, control))

95% CI

rs17002284

EP300

All subjects

0.012

Recessive

0.43 (13, 29; 284, 271)

0.22 - 0.84

rs4820428

EP300

All subjects

0.011

Additive [(Dd) vs (dd)]

1.46 (132, 122; 87, 117)

1.00 - 2.11

    

   [(DD) vs (Dd)]

1.18 (78, 61; 132, 122)

0.78 - 1.79

  

All subjects

0.012

Dominant

1.54 (210, 183; 87, 117)

1.10 - 2.17

rs4820429

EP300

All subjects

0.046

Dominant

0.70 (75, 98; 222, 202)

0.49 - 0.99

  

White

0.041

Dominant

0.50 (22, 52; 37, 44)

0.26 - 0.50

rs1621700

TFAP2A

All subjects

0.041

Additive [(Dd) vs (dd)]

1.30 (131, 118; 138, 161)

0.92 - 1.81

    

   [(DD) vs (Dd)]

1.33 (28, 19; 131, 118)

0.70 - 2.50

rs3798691

TFAP2A

Hispanic

0.015

Additive [(Dd) vs (dd)]

1.78 (48, 23; 143, 122)

1.04 - 3.19

    

   [(DD) vs (Dd)]

1.40 (9, 3; 47, 22)

0.35 - 5.70

  

Hispanic

0.022

Dominant

1.84 (56, 26; 143, 122)

1.13 - 3.25

  

Hispanic-FB

0.049

Dominant

1.82 (44, 19; 122, 92)

1.00 - 3.40

rs533558

TFAP2A

Hispanic-NB

0.038

Additive [(Dd) vs (dd)]

3.00 (18, 14; 6, 14)

0.92 - 9.80

    

   [(DD) vs (Dd)]

1.40 (9, 5; 18, 14)

0.38 - 5.12

  

Hispanic-NB

0.032

Dominant

3.32 (27, 19; 6, 14)

1.08 - 10.18

rs17616105

CARM1

Hispanic

0.0

Recessive

n/a (6, 0; 193, 148)

n/a

  

White

0.004

Additive [(Dd) vs (dd)]

0.48 (15, 36; 43,50)

0.23 - 1.00

    

   [(DD) vs (Dd)]

0.24 (1,10; 15,36)

0.03 - 2.04

  

White

0.010

Dominant

0.40 (16, 46; 43, 50)

0.40 - 0.20

rs1131431

CITED2

White

0.027

Recessive

5.32 (6, 2; 53, 94)

1.04 - 27.30

rs129986

CREBBP

All subjects

0.005

Additive [(Dd) vs (dd)]

0.27 (6, 21; 291, 279)

0.11 - 0.69

    

   [(DD) vs (Dd)]

n/a (0, 0; 6, 21)

n/a

  

All subjects

0.003

Dominant

0.27 (6, 21; 291, 279)

0.11 - 0.69

  

White

0.014

Additive [(Dd) vs (dd)]

n/a (0, 10; 59, 86)

n/a

    

   [(DD) vs (Dd)]

n/a (0, 0; 0, 10)

n/a

  

White

0.010

Dominant

n/a (0, 10; 59, 86)

n/a

CITED2

Only one of the two SNPs genotyped was fully analyzed. SNP rs1131431 showed a genotypic association (OR = 5.32, 95% CI: 1.04~27.30) based on a recessive mode of inheritance, specifically in the White population. It is noteworthy that the confidence interval had a wide range, suggesting that the estimate may be imprecise due to the small number of White cases and controls with the variant. This SNP, however, was previously associated with a modest increase in risk for spina bifida and congenital heart defects [14].

EP300

Among the 8 SNPs analyzed, the G allele of SNP rs4820428 was over-represented in spina bifida cases (OR = 1.30, 95% CI: 1.01~1.67) in all subjects. Analyses showed that rs4820428 was associated with spina bifida risk under a dominant model (OR = 1.54 95%CI: 1.10~2.17). The minor allele of rs4820429 (C) showed a reduced risk in the Whites (OR = 0.50, 95% CI: 0.26~0.50) and in the whole dataset (OR = 0.70, 95% CI: 0.49~0.99) under a dominant model. Minor allele of rs17002284 (G) also showed a reduced risk (OR = 0.43, 95%CI: 0.22~0.84), but under a recessive model. These three SNPs were in linkage disequilibrium. Subsequent analysis showed that haplotype ACGG (rs17002284-rs4822006-rs4820428-rs4820429) accounted for 50.3% of all haplotypes in the Whites and was over-represented in the white cases (OR = 1.30, 95%CI: 1.01~1.67). It is noteworthy that this high risk haplotype contains the high risk alleles for rs17002284 (A), rs4820428 (G) as well as rs4820429 (G) (Table 5).
Table 5

Haplotype associations (only significant associations are shown)

Haplotype Block

Frequency

P Value

Odds Ratio (case, control)

95% CI

TFAP2A-rs537112, rs533558, rs303050, rs3798694, and rs3798691 in Hispanic

AGCGC

0.133

0.0205

1.73 (63.0 : 335.0, 29.0 : 267.0)

1.08-2.77

GATGG

0.516

0.2019

0.82 (197.0 : 201.0, 161.0 : 135.0)

0.61-1.11

GGTGG

0.201

0.8135

0.96 (78.9 : 319.1, 60.8 : 235.2)

0.66-1.39

GGCAG

0.058

0.4974

1.26 (25.0 : 373.0, 15.0 : 281.0)

0.65-2.43

AGCGG

0.041

0.3207

0.69 (13.9 : 384.1, 14.8 : 281.2)

0.33-1.45

GGCGG

0.028

0.6568

0.81 (10.1 : 387.9, 9.2 : 286.8)

0.33-2.00

AGTGG

0.021

0.9639

0.97 (8.1 : 389.9, 6.2 : 289.8)

0.34-2.79

EP300- rs17002284, rs4822006, rs4820428 and rs4820429 in non-Hispanic white

ACGG

0.503

0.0377

1.30 (276.0 : 240.0, 229.0 : 259.0)

1.01-1.67

GCAG

0.245

0.1665

0.82 (117.0 : 399.0, 129.0 : 359.0)

0.61-1.09

ATAC

0.163

0.054

0.72 (73.0 : 443.0, 91.0 : 397.0)

0.51-1.00

ATAG

0.072

0.8074

1.06 (38.0 : 478.0, 34.0 : 454.0)

0.66-1.72

ACAG

0.015

0.2348

1.91 (10.0 : 506.0, 5.0 : 483.0)

0.65-5.63

TFAP2

Among the 9 SNPs analyzed, rs303056 (C), rs3798691 (C), rs533558 (G) showed allelic association with spina bifida risk in Hispanics. Genotypic association analysis showed that rs3798691 was associated with spina bifida risk under a dominant model in Hispanics (OR = 1.78, 95% CI: 1.13~2.87). SNP rs533558 also showed an association under a dominant model, but only in native-born Hispanics (OR = 3.32, 95%CI: 1.08~10.18). Subsequent haplotype analysis predicted two haplotype blocks in Hispanics. Haplotype AGCGC of block1 (rs537112- rs533558-rs303050-rs3798694-rs3798691) had an average frequency of 0.133 and was associated with an increased risk, OR = 1.73 (1.08-2.77) compared to all other haplotypes. Since no high risk SNP has been discovered, these high risk blocks will be thoroughly sequenced to search for other variants (Table 5).

CREBBP

Among the 8 SNPs analyzed, the heterozygous status of SNP rs129986 (TC) was associated with a reduced risk in all subjects (OR = 0.27, 95% CI: 0.11~0.69). The homozygous status of the minor allele, CC, was not observed. The TC genotype was observed in only 6 cases and they were all Hispanics.

CARM1

6 SNPs were genotyped. In Whites, the minor allele (C) of rs17616105 showed a reduced risk with OR = 0.41 (95%CI: 0.22~0.75). Genotype analysis showed that this effect followed a dominant inheritance model (ORCC+CT = 0.40, 95% CI: 0.20~0.40), and was not observed in the Hispanics.

ALX1

3 SNPs were genotyped. No association was observed between any SNP and spina bifida risk. It is known that the Cart1 knockout mouse responses to maternal supplementation with folic acid [23]. The majority of the DNA samples for this study were collected after folic acid fortification is implied in the USA, which might interact with the genotyping effect; however, our study lacks the statistic power to analyze the gene-environment interaction.

To our knowledge, this is the first study evaluating human CREBBP, EP300, CARM1, TFAP2A, and ALX1 genes as possible risk factors for spina bifida. Association between CITED2 and spina bifida has been studied before, and results from our current study are consistent with the previous findings [14]. Modest associations were observed between spina bifida risk and TFAP2A, EP300, CITED2, CREBBP1 and CARM1. No association was observed in ALX1 gene. However, given the number of comparisons made, relatively few associations emerged. Although NTDs are multifactorial diseases, it cannot be excluded that the studied genes may contain rare mutations that cause some of the NTDs. With the most advanced next-generation sequencing technique being available, we may be able to discover such rare variants in our study population.

The strengths of this study include its population-based ascertainment of cases and controls and its evaluation of race/ethnicity as potential modifiers of risk in the presence of variant genotypes and haplotypes. A major limitation of our study was the small sample size, which reduced the statistical power of analyses. Replication of some of the modest findings in a larger sample set may be warranted.

Conclusions

We have observed modest associations with risk of spina bifida in CITED2, EP300, CREBBP, TFAP2A and CARM1 genes but not ALX1 gene. These modest associations were not statistically significant after correction for multiple comparisons. Future effort will focus on searching for potential functional variants and rare causal mutations in these potential candidate genes.

Abbreviations

CREB

cAMP response element binding protein

CRE

cyclic AMP-responsive

CITED2

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2

EP300

E1A binding protein p300 (Alias: p300)

CREBBP

CREB binding protein (Alias: CBP)

TFAP2A

transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) (Alias: AP-2)

CARM1

coactivator-associated arginine methyltransferase 1

ALX1

ALX homeobox 1 (Alias: CART1).

Declarations

Acknowledgements

This research was supported in part by funds from NIH grants R01 NS050249 (GMS), R01 HD053509 (RMG), P20 RR017702 from the COBRE program of the National Center for Research Resources (RMG), as well as a contract from the Centers for Disease Control and Prevention, Center of Excellence Award UO1/DD000491. We thank the California Department of Public Health Maternal Child and Adolescent Health Division for providing biological samples and data for these analyses. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the California Department of Public Health. The authors thank Ms. Consuelo Vega for her technical assistance.

Authors’ Affiliations

(1)
Institute of Biosciences and Technology, Texas A&M University System Health Science Center
(2)
Stanford University
(3)
University of Louisville Birth Defects Center
(4)
Children's Hospital Oakland Research Institute
(5)
Dell Pediatric Research Institute, UT Austin

References

  1. Bamforth SD, Braganca J, Eloranta JJ, Murdoch JN, Marques FI, Kranc KR, Farza H, Henderson DJ, Hurst HC, Bhattacharya S: Cardiac malformations, adrenal agenesis, neural crest defects and exencephaly in mice lacking Cited2, a new Tfap2 co-activator. Nat Genet. 2001, 29: 469-474. 10.1038/ng768.View ArticlePubMedGoogle Scholar
  2. Barbera JP, Rodriguez TA, Greene ND, Weninger WJ, Simeone A, Copp AJ, Beddington RS, Dunwoodie S: Folic acid prevents exencephaly in Cited2 deficient mice. Hum Mol Genet. 2002, 11: 283-293. 10.1093/hmg/11.3.283.View ArticlePubMedGoogle Scholar
  3. Bhattacherjee V, Horn KH, Singh S, Webb CL, Pisano MM, Greene RM: CBP/p300 and associated transcriptional co-activators exhibit distinct expression patterns during murine craniofacial and neural tube development. Int J Dev Biol. 2009, 53: 1097-1104. 10.1387/ijdb.072489vb.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RC, Masuno M, Tommerup N, van Ommen GJ, Goodman RH, Peters DJ, et al: Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature. 1995, 376: 348-351. 10.1038/376348a0.View ArticlePubMedGoogle Scholar
  5. Tanaka Y, Naruse I, Hongo T, Xu M, Nakahata T, Maekawa T, Ishii S: Extensive brain hemorrhage and embryonic lethality in a mouse null mutant of CREB-binding protein. Mech Dev. 2000, 95: 133-145. 10.1016/S0925-4773(00)00360-9.View ArticlePubMedGoogle Scholar
  6. Weninger WJ, Lopes Floro K, Bennett MB, Withington SL, Preis JI, Barbera JP, Mohun TJ, Dunwoodie SL: Cited2 is required both for heart morphogenesis and establishment of the left-right axis in mouse development. Development. 2005, 132: 1337-1348. 10.1242/dev.01696.View ArticlePubMedGoogle Scholar
  7. Yadav N, Lee J, Kim J, Shen J, Hu MC, Aldaz CM, Bedford MT: Specific protein methylation defects and gene expression perturbations in coactivator-associated arginine methyltransferase 1-deficient mice. Proc Natl Acad Sci USA. 2003, 100: 6464-6468. 10.1073/pnas.1232272100.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Yao TP, Oh SP, Fuchs M, Zhou ND, Ch'ng LE, Newsome D, Bronson RT, Li E, Livingston DM, Eckner R: Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell. 1998, 93: 361-372. 10.1016/S0092-8674(00)81165-4.View ArticlePubMedGoogle Scholar
  9. Zhao Q, Behringer RR, de Crombrugghe B: Prenatal folic acid treatment suppresses acrania and meroanencephaly in mice mutant for the Cart1 homeobox gene. Nat Genet. 1996, 13: 275-283. 10.1038/ng0796-275.View ArticlePubMedGoogle Scholar
  10. Kitabayashi I, Aikawa Y, Nguyen LA, Yokoyama A, Ohki M: Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. EMBO J. 2001, 20: 7184-7196. 10.1093/emboj/20.24.7184.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Xu W, Chen H, Du K, Asahara H, Tini M, Emerson BM, Montminy M, Evans RM: A transcriptional switch mediated by cofactor methylation. Science. 2001, 294: 2507-2511. 10.1126/science.1065961.View ArticlePubMedGoogle Scholar
  12. Jayne S, Rothgiesser KM, Hottiger MO: CARM1 but not its enzymatic activity is required for transcriptional coactivation of NF-kappaB-dependent gene expression. J Mol Biol. 2009, 394: 485-495. 10.1016/j.jmb.2009.09.032.View ArticlePubMedGoogle Scholar
  13. Chen SL, Loffler KA, Chen D, Stallcup MR, Muscat GE: The coactivator-associated arginine methyltransferase is necessary for muscle differentiation: CARM1 coactivates myocyte enhancer factor-2. J Biol Chem. 2002, 277: 4324-4333. 10.1074/jbc.M109835200.View ArticlePubMedGoogle Scholar
  14. Volcik KA, Zhu H, Finnell RH, Shaw GM, Canfield M, Lammer EJ: Evaluation of the Cited2 gene and risk for spina bifida and congenital heart defects. Am J Med Genet A. 2004, 126A: 324-325. 10.1002/ajmg.a.20578.View ArticlePubMedGoogle Scholar
  15. Yin Z, Haynie J, Yang X, Han B, Kiatchoosakun S, Restivo J, Yuan S, Prabhakar NR, Herrup K, Conlon RA, et al: The essential role of Cited2, a negative regulator for HIF-1alpha, in heart development and neurulation. Proc Natl Acad Sci USA. 2002, 99: 10488-10493. 10.1073/pnas.162371799.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Braganca J, Eloranta JJ, Bamforth SD, Ibbitt JC, Hurst HC, Bhattacharya S: Physical and functional interactions among AP-2 transcription factors, p300/CREB-binding protein, and CITED2. J Biol Chem. 2003, 278: 16021-16029. 10.1074/jbc.M208144200.View ArticlePubMedGoogle Scholar
  17. Zhang J, Hagopian-Donaldson S, Serbedzija G, Elsemore J, Plehn-Dujowich D, McMahon AP, Flavell RA, Williams T: Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2. Nature. 1996, 381: 238-241. 10.1038/381238a0.View ArticlePubMedGoogle Scholar
  18. Schorle H, Meier P, Buchert M, Jaenisch R, Mitchell PJ: Transcription factor AP-2 essential for cranial closure and craniofacial development. Nature. 1996, 381: 235-238. 10.1038/381235a0.View ArticlePubMedGoogle Scholar
  19. Nottoli T, Hagopian-Donaldson S, Zhang J, Perkins A, Williams T: AP-2-null cells disrupt morphogenesis of the eye, face, and limbs in chimeric mice. Proc Natl Acad Sci USA. 1998, 95: 13714-13719. 10.1073/pnas.95.23.13714.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Iioka T, Furukawa K, Yamaguchi A, Shindo H, Yamashita S, Tsukazaki T: P300/CBP acts as a coactivator to cartilage homeoprotein-1 (Cart1), paired-like homeoprotein, through acetylation of the conserved lysine residue adjacent to the homeodomain. J Bone Miner Res. 2003, 18: 1419-1429. 10.1359/jbmr.2003.18.8.1419.View ArticlePubMedGoogle Scholar
  21. Zhao GQ, Zhou X, Eberspaecher H, Solursh M, de Crombrugghe B: Cartilage homeoprotein 1, a homeoprotein selectively expressed in chondrocytes. Proc Natl Acad Sci USA. 1993, 90: 8633-8637. 10.1073/pnas.90.18.8633.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Zhao GQ, Eberspaecher H, Seldin MF, de Crombrugghe B: The gene for the homeodomain-containing protein Cart-1 is expressed in cells that have a chondrogenic potential during embryonic development. Mech Dev. 1994, 48: 245-254. 10.1016/0925-4773(94)90063-9.View ArticlePubMedGoogle Scholar
  23. Harris MJ: Insights into prevention of human neural tube defects by folic acid arising from consideration of mouse mutants. Birth Defects Res A Clin Mol Teratol. 2009, 85: 331-339. 10.1002/bdra.20552.View ArticlePubMedGoogle Scholar
  24. Croen LA, Shaw GM, Jensvold NG, Harris JA: Birth defects monitoring in California: a resource for epidemiological research. Paediatr Perinat Epidemiol. 1991, 5: 423-427. 10.1111/j.1365-3016.1991.tb00728.x.View ArticlePubMedGoogle Scholar
  25. De La Vega FM, Isaac HI, Scafe CR: A tool for selecting SNPs for association studies based on observed linkage disequilibrium patterns. Pac Symp Biocomput. 2006, 487-498. full_text.Google Scholar
  26. Baluja KF, Park J, Myers D: Inclusion of immigrant status in smoking prevalence statistics. Am J Public Health. 2003, 93: 642-646. 10.2105/AJPH.93.4.642.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Curry CJ, Lammer EJ, Nelson V, Shaw GM: Schizencephaly: heterogeneous etiologies in a population of 4 million California births. Am J Med Genet A. 2005, 137: 181-189.View ArticlePubMedGoogle Scholar
  28. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B, Statistical methodology. 1995, 57: 289-Google Scholar
  29. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/11/141/prepub

Copyright

© Lu et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement